CEO
CI
Cypre Inc.
5/10Traction
Cypre Inc. develops proprietary hydrogel-based 3D in vitro tumor microenvironment models that enable pharmaceutical and biotech companies to evaluate drug efficacy and mechanisms of action. These models address the challenge of drug resistance in cancer treatment by providing translatable insights for therapeutic innovation.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$875KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Kluz VenturesNo round attributed
- kluzventures.com (opens in a new tab)investor website
Funding rounds are not available yet.
Founders
Product
Features
- Cypre Inc. develops proprietary hydrogel-based 3D in vitro tumor microenvironment models that enable pharmaceutical and biotech companies to evaluate drug efficacy and mechanisms of action. These models address the challenge of drug resistance in cancer treatment by providing translatable insights for therapeutic innovation.